Heptares, Daiichi Sankyo to develop small molecules for pain treatment

By Melissa Fassbender

- Last updated on GMT

Heptares, Daiichi Sankyo to develop small molecules for pain treatment

Related tags Daiichi sankyo Pharmacology

Heptares Therapeutics has entered into a drug discovery and licensing agreement with Daiichi Sankyo – providing further validation of the company’s structure-based drug design approach, says CEO.

Malcolm Weir, Heptares CEO told us the agreement is a single target deal aimed at delivering novel small molecule drug candidates.

Heptares, a wholly owned subsidiary of Sosei Group Corporation that focuses on medicines targeting G protein-coupled receptor (GPCRs), will receive an upfront payment of $4m and research funding of approximately $8m.

The company is also eligible to receive additional research, development, and commercialization milestone payments in addition to royalties on net sales of products resulting from the alliance.

Per the agreement, Heptares will apply its StaR platform to engineer thermally stabilized forms of a GPCR nominated by Daiichi Sankyo, which it says plays a “crucial role in relieving pain​.”

Heptares will also apply its structure-based design capabilities, including advanced structural biology and rational drug design approaches, X-ray crystallography, and fragment screening.

Structural insights may enable Heptares and Daiichi to design a much more selective drug with a better efficacy/safety profile​,” Weir added.

Daiichi will be responsible for taking promising drug candidates through clinical trials and commercialization.

The first step is to create the stabilized version of the GPCR target (the StaR protein), and undertake the steps needed to generate high resolution X-ray structural information​,” Weir explained.

Additionally, he said the agreement is further validation of its GPCR Structure-based drug design (SBDD) approach and adds to the register of pharma partners signed up in recent years, including Allergan, AstraZeneca, Teva, and Pfizer​.

It also provides revenues to enable Heptares/Sosei to advance development of its own proprietary pipeline, Weir commented.

(Feature image: iStock/alice-photo)

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars